-
3 Big Drugs on Market in early 2011 (Mcap 2,8 M)LOW FLOAT
Puramed will launch 3 big drugs in 1Q 2011.
If you like EDAP you will like PMBS too .Market cap of 2,8 million$ is massive undervalued . This stock is under Radar .
Get in now before the stock gets Discovered !!! Easy money at this level .
Puramed (PMBS.PK)
Market Cap: 2,8 M$
Cash : 5 M$ agreement http://puramedbioscience.com/PR/2010...201%202010.pdf
Price 0,19 $
Shares Out: 14.1 M ...( 9 million shares held by insiders )
Low Float : 5 M
A MUST READ ......
http://www.puramedbioscience.com/Pur...ile-4.2010.pdf
Only a few shares available below 1 Dollar
PMBS PuraMed BioScience, Inc.: Summary, Stock Quote & Trades for PuraMed BioScience, Inc. - OTCMarkets.com
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 14,129,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
-
-
No kidding, up 75%+...the master has some pull in this holiday market indeed
-
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
The second, longer term, opportunity is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a “new kind of product line.” Our product line will consist of ‘alternative’ remedies for common ailments, marketed to the masses. Most consumers want products that are, first of all, effective and safe. By applying hard science to ‘natural’ products, management believes it is possible to build a line wherein each product delivers better performance with fewer side effects than its chemical counterparts. With effective marketing, these products will be embraced by the majority, many of whom prefer ‘natural’ alternatives, provided there is no need to sacrifice performance or convenience.
PuraMed BioScience, Inc will enter the OTC (Over-The-Counter) medicine marketplace by employing direct to consumer marketing and applying broad retail distribution and effective marketing to several unique products now developed and known to be effective. The company intends to launch its first two retail products within six months and leverage that success to ultimately become a leader in the OTC medicine marketplace.
-
Please click link and look at ASK !!
PMBS PuraMed BioScience, Inc.: Summary, Stock Quote & Trades for PuraMed BioScience, Inc. - OTCMarkets.com
ASK:
VERT 0.275 5000 << Last shares then jump to 49c
HDSN 0.49 5000 <<
-
RUNUP HAS JUST BEGUN ...ENJOY THE RIDE TO NEW HIGHS .
Still time to get in very cheap .
-
Breakout could start any time now ......
Buy Confirmed
PMBS PURAMED BIOSCIENCE INC
(otcstockreview) Analyst says , Puramed is a 5-10 Bagger :
Summary
Now is an exciting time for PMBS and its shareholders. To date it has kept a relatively low profile, choosing
to focus on building value for itself by developing its technology and brands rather than market visibility.
As the Company rolls out new products and expands the awareness of its existing brands, we believe
investors will certainly notice the stock. As a result, the price and trading volume of PMBS should
increase as investors learn about this incredible opportunity. With a management team that has "done
this before" to the tune of a $70 million company, we believe sales of products introduced by PMBS will
be very strong. With wide profit margins on the products sold by PMBS, in our opinion, shareholders will
benefit from a higher stock price as revenues and profits increase.
Growth oriented investors should consider adding shares of PMBS to their portfolio at these levels. Once
its products show up on the shelves of major retailers and the stock begins to be more widely followed
by Wall Street, investors could see five to ten-fold returns.
-
PuraMed BioScience, Inc. Announces Completion of Manuscript of Clinical Study of LipiGesic(TM) M and Submission to Top-Ranked Medical Journal - Yahoo! Finance
PuraMed BioScience, Inc. Announces Completion of Manuscript of Clinical Study of LipiGesic(TM) M and Submission to Top-Ranked Medical Journal
Last chance to buy at 75c before it jumps over 1 US$ ! THIS LOW FLOAT STOCK COULD JUMP TO $6++ WITHIN SECONDS . GOOD LUCK ALL !
PMBS PuraMed BioScience, Inc.: Summary, Stock Quote & Trades for PuraMed BioScience, Inc. - OTCMarkets.com
MPID Ask Price Size Date/Time
NITE ---0.75------5000 <<
DOMS ---1.40------500 <<
HDSN ---1.50------500
VFIN ---1.70------500
-
Junior Member
- Rep Power
- 74
What happened to this? Dont see any reson of this going back to $0.10?
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
Forum Rules
LinkBack URL
About LinkBacks
Reply With Quote
